Navigation Links
Halozyme Therapeutics Announces Implementation of Development Focused Strategy
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a focusing of its resources on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and supporting strategic alliances with Roche and Baxter such as validation of Halozyme's commercial scale manufacturing process to produce kilogram quantities of enzyme. Halozyme will continue full development of its Phase 2 Ultrafast Insulin, Phase 1 PEGPH20, and preclinical HTI-501 programs, but will decrease research relating to the discovery and preclinical assessment of new compounds, resulting in a reduction in the workforce of approximately 25 percent. The company expects to incur a one-time charge in the fourth quarter related to the workforce reduction that will be mostly offset by reduced payroll expenses during the quarter. The implementation of this strategy is not expected to impact previous net cash burn guidance, and management reiterates its guidance of $40 to $45 million of net cash burn for 2010.  

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

"A decade's worth of investment in discovery and preclinical research from 2000 to 2010 has resulted in two FDA approved products, three late stage product candidates with Roche and Baxter, and three exciting proprietary programs with best-in-class or first-in-class potential," stated Jonathan Lim, M.D., president and CEO. "This development focused strategy combined with our partners' achie
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
2. Halozyme Therapeutics Announces Public Offering of Common Stock
3. Halozyme Provides HYLENEX® Product Reintroduction Update
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
7. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
8. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
9. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Inc. has initiated Phase I/II clinical studies with ... Phase I/II safety and tolerability study in 18 ... cancer has begun,enrolment in the US. Secondary objectives ... vaccine to induce prostate antigen-specific immune,responses, as well ...
... of Clinical Oncology meeting indicate ... data., PRINCETON, N.J., June 3 Celator ... clinical trial in patients,with advanced colorectal cancer. CPX-1 ... on the company,s proprietary,CombiPlex(TM) technology. The results were ...
Cached Medicine Technology:BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:5/29/2015)... News: 2015-2016 Oil Market Forecast, Company: ... http://www.carsonenergy.com , In July, 2014, the price ... boom in US shale production and increased production from ... market share from US shale producers, started producing close ... oil out into the marketplace, they could push oil ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 Wimbledon ... provides vascular, electrocardiogram (EKG), echocardiogram and NCV testing, ... most recent guidelines for EKG interpretation of athletes. ... leading cause of death during athletic activity. New findings ... the continued discussion to improve cardiac safety in athletes. ...
(Date:5/29/2015)... Astoria, NY (PRWEB) May 29, 2015 Thursday, ... United States. People from all walks of life came ... , Because Red Nose Day is a campaign dedicated to ... by simply having fun and making people laugh, the people ... their clinic in Astoria. Here they provided food, fun ...
(Date:5/29/2015)... Houston, TX (PRWEB) May 29, 2015 ... lorcaserin, is an FDA approved prescription diet medication. ... treatment of obesity when individuals have a BMI >30. ... BMI >27 with at least one additional weight-related health ... cholesterol. , Belviq’s main function for weight ...
(Date:5/28/2015)... May 28, 2015 External Counterpulsation (EECP/ECP) ... all over the United States. There are a growing ... who can experience symptoms of angina and these patients ... stents and/or bypass surgery. , “No option” patients are ... coronary artery disease that is considered unacceptable for heart ...
Breaking Medicine News(10 mins):Health News:Breaking News: Carson Energy Releases 2015-2016 Oil Forecast 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2
... ALEXANDRIA, Va., March 26 The following is,an op-ed ... Community,Pharmacists Association:, With a renewed national spotlight on ... note as well the often,over-looked issue of crimes against ... powerful pain killers and other controlled,substances is a federal ...
... March 26 Golub Capital today announced ... debt financing (through Golub,Capital,s proprietary GOLD facility) ... market leader providing precision tubing solutions to ... in Placentia, Calif.,ExtruMed,s products are used in ...
... to reinvent excellence in global,healthcare delivery, WASHINGTON, ... Tatweer, the world,s first integrated healthcare free zone,announced ... Officer of,their recently launched University Hospital. The University ... of life sciences research, post,graduate medical education, and ...
... Technologies, Inc.,which is developing innovative, patient-friendly medical ... Obstructive Pulmonary Disease,(COPD), cystic fibrosis, and influenza ... million in its second round of venture ... Caufield & Byers (KPCB) with participation from,existing ...
... among pet owners, JEFFERSONVILLE, Ind., March 26 ... your usual route through the park...,and only after seeing ... of broken glass a few steps behind. What do ... respond to an emergency with,their pet. Each year in ...
... Sun Exposure in Light of New Evidence Showing ... WASHINGTON, March 26 Today, the Indoor,Tanning Association ... to rethink sun-tanning and criticizing,dermatologists and the sunscreen ... sun., The advertising blitz begins with a ...
Cached Medicine News:Health News:Independent Pharmacies Protecting You and Your Medications 2Health News:Golub Capital Provides $29.5 Million GOLD Facility in Support of the Recapitalization of ExtruMed 2Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 2Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 3Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 4Health News:Dubai Healthcare City Announces Appointment of James Kingsbury as Chief Executive Officer of University Hospital 5Health News:Breathe Technologies, Inc. Closes on $15 Million in Venture Funding Led by Kleiner Perkins Caufield & Byers 2Health News:Pets Benefit from First Aid Too 2Health News:Indoor Tanning Association Launches Campaign Attacking Melanoma Hype 2
... Complete MoisturePlus is ... multi-purpose solution to offer ... essential electrolytes and taurine. ... protein, stores and conditions ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Light weight adjustable trial frame - Child...
Half Trial Frames with precision engineering and lightweight material....
Medicine Products: